Surveillance and Screening Protocols
Surveillance and screening protocols describe how people at increased genetic risk are monitored over time so that disease can be detected early or prevented. For many hereditary conditions, a confirmed genetic result translates into a structured schedule of examinations and tests, often starting at a defined age and repeated at defined intervals, tailored to the risks implied by the specific condition.
Definition
Surveillance and screening protocols are structured, risk-based schedules of monitoring (examinations, imaging, or tests) applied to individuals at increased genetic risk, with the aim of early detection or prevention of associated disease.
Scope
The topic covers the rationale for risk-based surveillance, how protocols translate genetic risk into monitoring schedules, and how such protocols are codified in guidelines. It is descriptive of the structure and logic of surveillance; it does not specify intervals, ages, or modalities for any individual patient and is not a substitute for the relevant condition-specific guideline.
Core questions
- How is genetic risk translated into a concrete surveillance schedule?
- What distinguishes surveillance of a high-risk individual from population screening of average-risk people?
- How are surveillance protocols established, revised, and kept current in guidelines?
Key concepts
- Risk-based surveillance
- Early detection
- Screening interval and start age
- High-risk versus population screening
- Guideline-defined protocols
- Condition-specific monitoring
Mechanisms
Surveillance reframes a static genetic risk as an ongoing monitoring plan. A confirmed pathogenic result implies a probability of associated disease, and surveillance protocols convert that probability into recommendations about which organs to monitor, by which modality, beginning at which age, and at which interval. Lynch syndrome is a well-documented example: European expert guidelines define colonoscopic and other surveillance for confirmed carriers. Such protocols are population-level instruments codified in guidelines, then applied to individuals through the clinical team.
Clinical relevance
This topic explains why a genetic diagnosis is often accompanied by a lifelong monitoring plan and how that plan is structured by risk. It clarifies the difference between targeted surveillance of high-risk individuals and broad population screening. The content is descriptive of how protocols are organized; specific schedules belong to the relevant guidelines and clinical judgment, not to this reference entry.
Evidence & guidelines
Surveillance protocols are typically issued as condition-specific clinical guidelines. The revised European guidelines for Lynch syndrome (Vasen et al., 2013) and the NCCN Genetic/Familial High-Risk Assessment guidelines illustrate how surveillance is codified and periodically revised by expert panels.
Key figures
- Hans Vasen
- Jeannette Haggerty
Related topics
Seminal works
- vasen-2013
Frequently asked questions
- How does a genetic result become a surveillance schedule?
- A confirmed result implies a probability of associated disease; guideline panels translate that risk into recommendations about which organs to monitor, by which method, starting at which age, and at which interval.
- Is surveillance of a high-risk individual the same as population screening?
- No. Population screening targets average-risk people broadly, whereas surveillance applies a more intensive, risk-tailored monitoring plan to individuals known to be at increased genetic risk.